Prognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain - Quiz - MDSpire

Prognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain

  • By

  • Sina M. Pütz

  • Marie Engelhard

  • Sebastian M. Wingen-Heimann

  • David F. Brilz

  • Brune Akrich

  • Heike Kohl

  • Annika Y. Classen

  • Carlota Gudiol

  • Enric Sastre-Escola

  • Franziska C. Trudzinski

  • Arturo Olivares Rivera

  • Eva Lücke

  • Tadeusz Marczewski

  • Ayham Daher

  • Stephan Eisenmann

  • Jacqueline Schmitz

  • Anke Reinacher-Schick

  • Julia von Tresckow

  • Rebekka Mispelbaum

  • Tessa Hattenhauer

  • J. Janne Vehreschild

  • May 4, 2026

  • 0 min

Share

Original Source(s)

Prognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain

  • by Sina M. Pütz, Marie Engelhard, Sebastian M. Wingen-Heimann, David F. Brilz, Brune Akrich, Heike Kohl, Annika Y. Classen, Carlota Gudiol, Enric Sastre-Escola, Franziska C. Trudzinski, Arturo Olivares Rivera, Eva Lücke, Tadeusz Marczewski, Ayham Daher, Stephan Eisenmann, Jacqueline Schmitz, Anke Reinacher-Schick, Julia von Tresckow, Rebekka Mispelbaum, Tessa Hattenhauer, J. Janne Vehreschild

  • May 4, 2026

Related Content

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma

Case report and literature review: the effect of surgical management in intrathoracic pseudomyxoma peritonei

Dosimetric and clinical outcomes of stereotactic body radiotherapy for primary lung cancer: isocenter-based vs. volume-based prescription